Filter by Year
Acer Therapeutics Announces Full Enrollment of Part B in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders
Part A Successfully Completed and Optimal Formulation of ACER-001 Identified
Results of Part B Expected in Q1 2020 with a Planned NDA Submission in Q1 2021
NEWTON, MA – Dec. 16, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of Part B of its pivotal trial evaluating bioavailability and bioequivalence of ACER-001 (sodium phenylbutyrate) for […]
Read MoreAcer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
NEWTON, MA – Nov. 13, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2019 and provided an update on the Company’s recent […]
Read MoreAcer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders
Results Expected in Q1 2020 with a Planned NDA Submission in Q1 2021
NEWTON, MA – October 28, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of Part A in a pivotal trial evaluating bioavailability and bioequivalence of ACER-001 for the treatment […]
Read MoreAcer Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference
NEWTON, MA – August 27, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a corporate overview at the 21st Annual H.C. Wainwright Global Investment Conference […]
Read MoreAcer Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
NEWTON, MA – August 13, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2019 and provided an update on the Company’s recent […]
Read MoreAcer Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
NEWTON, MA – August 1, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference being held […]
Read MoreAcer Therapeutics to Host Conference Call and Webcast to Discuss Update on its Pipeline Programs
Call to take place on Wednesday, July 31 at 11:00 am Eastern Time
NEWTON, MA – July 25, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it will host a conference call and webcast on Wednesday, July 31, 2019 at 11:00 am Eastern Time […]
Read MoreAcer Therapeutics Announces Restructuring and Update on Pipeline Programs
Restructuring expected to extend cash runway through end of 2020
Acer plans to discuss EDSIVO™ CRL with FDA and will continue to advance additional pipeline products
NEWTON, MA – July 5, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced a corporate restructuring and update on its pipeline programs. Acer’s headcount has been reduced from 48 to 19 […]
Read MoreAcer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in vEDS Patients
NEWTON, MA – June 25, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its […]
Read MoreAcer Therapeutics Announces Poster Presentation at Society for Vascular Medicine Annual Meeting
Pilot study using claims database suggests that a minority of U.S. vEDS patients (34%) are being treated with antihypertensive medications
Data show no significant difference in clinical event rates in vEDS patients taking antihypertensive medications compared to those not taking an antihypertensive medication
NEWTON, MA – May 31, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the presentation and publication of results from its Pilot Study to Evaluate Effect of Antihypertensive Therapy on the […]
Read MoreAcer Therapeutics to Present at Upcoming Investor Conferences
NEWTON, MA – May 23, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a corporate overview at upcoming investor conferences in June, including: the William […]
Read MoreAcer Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Acer executing on pre-commercial launch plan for EDSIVO™ while growing and advancing its pipeline
NEWTON, MA – May 14, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2019 and provided an update on the Company’s recent […]
Read MoreAcer Therapeutics to Present at UBS Global Healthcare Conference
NEWTON, MA – May 7, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a corporate overview at the UBS Global Healthcare Conference, May 20-22, 2019 […]
Read MoreAcer Announces Publication of vEDS Patient Registry Data
NEWTON, MA – April 16, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical needs, today announced the publication of long-term data from a cohort of COL3A1-positive vEDS patients in the Journal of the American […]
Read MoreAcer Therapeutics to Participate in Upcoming Investor Conferences
NEWTON, MA – March 13, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today announced that Acer’s management team will provide a corporate overview at upcoming investor conferences in March and April, including: […]
Read MoreAcer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Acer continues to progress toward goals of commercializing EDSIVO™ and advancing pipeline
NEWTON, MA – March 7, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today reported financial results for the quarter and full year ended December 31, 2018 and provided an update on the […]
Read MoreAcer Therapeutics Announces In-license of Osanetant from Sanofi
Acer acquires worldwide rights to clinical-stage NK3 receptor antagonist
NEWTON, MA – January 2, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today announced that it has entered into an exclusive license agreement with Sanofi to acquire worldwide rights to osanetant, a […]
Read More